NASDAQ:EVAX Evaxion A/S (EVAX) Stock Price, News & Analysis $3.28 +0.03 (+0.77%) As of 10:54 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Evaxion A/S Stock (NASDAQ:EVAX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Evaxion A/S alerts:Sign Up Key Stats Today's Range$3.15▼$3.3550-Day Range$3.05▼$4.4152-Week Range$2.45▼$12.15Volume11,130 shsAverage Volume38,303 shsMarket Capitalization$27.31 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingModerate Buy Company Overview Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases. At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes. This approach aims to accelerate candidate discovery, refine antigen selection and enhance the precision of vaccine design. Evaxion’s pipeline encompasses a range of oncology programs targeting solid tumors as well as prophylactic vaccine programs focused on pathogens with high unmet medical need. Evaxion traces its origins to academic collaborations at the University of Copenhagen and has evolved into a publicly traded company listed on the NASDAQ under the ticker EVAX. The company is led by CEO Thomas Krogh Nielsen, who brings extensive experience in biotech product development and corporate strategy. Under his leadership, Evaxion has entered into research partnerships with academic institutions and industry partners to advance its pipeline through preclinical and early clinical milestones. Serving a global market, Evaxion collaborates with research centers and biopharma organizations across Europe and North America. Its AI-driven approach is positioned to address challenges in vaccine development by reducing time-to-candidate and improving the likelihood of clinical success. As Evaxion continues to expand its technology platform and advance its pipeline, the company aims to deliver novel immunotherapies and vaccines to patients worldwide.AI Generated. May Contain Errors. Read More Evaxion A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreEVAX MarketRank™: Evaxion A/S scored higher than 45% of companies evaluated by MarketBeat, and ranked 516th out of 844 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingEvaxion A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialEvaxion A/S has a consensus price target of $11.00, representing about 238.5% upside from its current price of $3.25.Amount of Analyst CoverageEvaxion A/S has only been the subject of 2 research reports in the past 90 days.Read more about Evaxion A/S's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Evaxion A/S are expected to grow in the coming year, from ($0.50) to $5.50 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evaxion A/S is -2.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evaxion A/S is -2.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEvaxion A/S has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Evaxion A/S's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.62% of the float of Evaxion A/S has been sold short.Short Interest Ratio / Days to CoverEvaxion A/S has a short interest ratio ("days to cover") of 0.86, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evaxion A/S has recently increased by 21.79%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEvaxion A/S does not currently pay a dividend.Dividend GrowthEvaxion A/S does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A MarketBeat FollowsOnly 1 people have added Evaxion A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Evaxion A/S insiders have not sold or bought any company stock.Percentage Held by Insiders41.64% of the stock of Evaxion A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions11.04% of the stock of Evaxion A/S is held by institutions.Read more about Evaxion A/S's insider trading history. Receive EVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evaxion A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EVAX Stock News HeadlinesEvaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus WorkshopJuly 1, 2026 | globenewswire.comEvaxion receives Prix Galien UK Award for Best digital health solutionJune 12, 2026 | globenewswire.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.July 9 at 1:00 AM | Stansberry Research (Ad)Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemiaJune 11, 2026 | globenewswire.comEvaxion A/S Sponsored ADRMay 21, 2026 | edition.cnn.comEvaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 CongressMay 12, 2026 | globenewswire.comEvaxion A/S (EVAX) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comEvaxion announces business update and first quarter 2026 financial resultsMay 7, 2026 | globenewswire.comSee More Headlines EVAX Stock Analysis - Frequently Asked Questions How have EVAX shares performed this year? Evaxion A/S's stock was trading at $4.77 at the start of the year. Since then, EVAX stock has decreased by 31.9% and is now trading at $3.25. How were Evaxion A/S's earnings last quarter? Evaxion A/S - Sponsored ADR (NASDAQ:EVAX) posted its earnings results on Thursday, May, 7th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by $0.43. Read the conference call transcript. When did Evaxion A/S's stock split? Evaxion A/S shares reverse split on Monday, January 13th 2025.The 1-5 reverse split was announced on Monday, December 30th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 10th 2025. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. When did Evaxion A/S IPO? Evaxion A/S (EVAX) raised $31 million in an IPO on Friday, February 5th 2021. The company issued 2,800,000 shares at $10.00-$12.00 per share. Oppenheimer & Co. acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager. How do I buy shares of Evaxion A/S? Shares of EVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Evaxion A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evaxion A/S investors own include PayPal (PYPL), Arista Networks (ANET), Tesla (TSLA), ChargePoint (CHPT), MercadoLibre (MELI), ASML (ASML). Company Calendar Last Earnings5/07/2026Today7/09/2026Next Earnings (Estimated)8/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (6m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 EVAX's financial health is in the Yellow zone, according to TradeSmith. EVAX has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MEDICAL INFO SYS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EVAX CIK1828253 Webwww.evaxion-biotech.com Phone45-5353-1850FaxN/AEmployees60Year Founded2008Price Target and Rating Average Price Target for Evaxion A/S$11.00 High Price Target$16.00 Low Price Target$9.00 Potential Upside/Downside+235.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.71 million Net MarginsN/A Pretax Margin-141.96% Return on Equity-73.56% Return on Assets-37.45% Debt Debt-to-Equity Ratio0.41 Current Ratio5.85 Quick Ratio5.85 Sales & Book Value Annual Sales$7.53 million Price / Sales3.63 Cash FlowN/A Price / Cash FlowN/A Book Value$2.04 per share Price / Book1.61Miscellaneous Outstanding Shares8,340,000Free Float4,867,000Market Cap$27.31 million OptionableNo Data Beta0.26 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:EVAX) was last updated on 7/9/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evaxion A/S - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Evaxion A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
